ABCL Latest Headlines

JonesTrading Sticks to Their Buy Rating for AbCellera Biologics (ABCL)

at www.tipranks.com (Sun, 27-Sep 5:55 PM)

AbCellera Biologics (ABCL) Receives a Hold from Goldman Sachs

at www.tipranks.com (Thu, 24-Sep 7:45 AM)

AbCellera Sets October 2026 Spotlight for ABCL635 Phase 2 Menopause Symptom Data

Market Chameleon (Thu, 17-Sep 7:10 AM)

AI Drug Discovery Advances: AbCellera’s Integrated Platform Draws Investor Focus as Industry Shifts to Function-Based Models

Market Chameleon (Wed, 19-Aug 9:16 AM)

AbCellera’s Strong Phase 2 Data Spotlight New Highs and Next Steps for ABCL635

Market Chameleon (Wed, 12-Aug 7:07 AM)

ABCL Phase 2 Results Spark Renewed Interest: 83% Reduction in Vasomotor Symptoms Stands Out

Market Chameleon (Tue, 11-Aug 11:21 AM)

ABCL635 Delivers Statistically Significant Phase 2 Results—50% Greater Reduction in Hot Flashes Over Placebo

Market Chameleon (Mon, 10-Aug 10:31 AM)

ABCL635’s Phase 2 Results Show 83% Mean Reduction in Hot Flashes—A Potential Shift for Menopausal Symptom Relief

Market Chameleon (Mon, 10-Aug 7:06 AM)

AbCellera Bolsters Liquidity With $100M in New Collaborations Despite Higher Q2 2026 Losses

Market Chameleon (Thu, 6-Aug 7:18 AM)

AbCellera Secures $28 Million Vertex Deal to Advance T-Cell Engager Platform for Autoimmune Therapies

Market Chameleon (Wed, 29-Jul 7:37 AM)

AbCellera Sets Q2 2026 Earnings Date—Clinical-Stage Pipeline Remains in Focus

Market Chameleon (Wed, 8-Jul 7:06 AM)

For Life Sciences AI, Data Is the New Moat: MindWalk’s Patent Filing Spotlights Industry Shift

Market Chameleon (Wed, 1-Jul 9:22 AM)